(UAMY) United States Antimony - NYSE
Sector: Basic Materials | Industry: Other Industrial Metals & Mining | Exchange: NYSE (USA) | Market Cap: 1.135m USD | Total Return: 175.5% in 12m
Avg Turnover: 75.7M
Qual. Beats: -1
Rev. Trend: 97.5%
Qual. Beats: -1
Warnings
Share dilution 15.8% YoY
Beneish M-Score 1.00 > -1.5 - likely earnings manipulation
Volatile
Tailwinds
Confidence
United States Antimony Corporation (UAMY) is a vertically integrated materials producer specializing in antimony, zeolite, and precious metals across North America. The company operates two primary segments: Antimony, which produces compounds for flame retardants, ammunition primers, and lead-acid batteries; and Zeolite, which provides minerals for environmental remediation, water filtration, and agricultural applications. Additionally, the firm recovers gold and silver as secondary products.
Antimony is classified as a critical mineral by the U.S. Department of the Interior due to its essential role in national defense and the energy sector, yet global supply is heavily concentrated in China and Russia. The zeolite market functions as an industrial mineral business where profitability often depends on proximity to end-markets and low processing costs. Investors can find further data on these industrial cycles at ValueRay.
Founded in 1968 and headquartered in Dallas, Texas, the company represents a niche domestic source within the diversified metals and mining sub-industry. Its business model relies on the industrial demand for specialized chemical additives and the increasing regulatory focus on domestic supply chain security for critical materials.
- Global antimony supply constraints drive higher prices and margin expansion
- Increased domestic ammunition production boosts demand for antimony trisulfide primers
- Zeolite segment revenue scales via environmental cleanup and agricultural applications
- Strategic shifts in North American smelting capacity impact antimony metal output
| Net Income: -16.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.40 > 0.02 and ΔFCF/TA -38.16 > 1.0 |
| NWC/Revenue: 89.75% < 20% (prev 100.1%; Δ -10.31% < -1%) |
| CFO/TA -0.14 > 3% & CFO -20.0m > Net Income -16.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.62 > 1.5 & < 3 |
| Outstanding Shares: last quarter (141.6m) vs 12m ago 15.79% < -2% |
| Gross Margin: 7.00% > 18% (prev 26.63%; Δ -19.64% > 0.5%) |
| Asset Turnover: 41.63% > 50% (prev 50.91%; Δ -9.27% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.24 (Total Current Assets 48.4m - Total Current Liabilities 13.4m) / Total Assets 148.0m |
| B: -0.38 (Retained Earnings -56.8m / Total Assets 148.0m) |
| C: -0.21 (EBIT TTM -19.8m / Avg Total Assets 93.8m) |
| D: 8.16 (Book Value of Equity 131.9m / Total Liabilities 16.2m) |
| Altman-Z'' = 7.46 = AAA |
| DSRI: 0.66 (Receivables 2.51m/1.97m, Revenue 39.0m/20.1m) |
| GMI: 3.81 (GM 26.63% / 7.00%) |
| AQI: 18.20 (AQ_t 0.36 / AQ_t-1 0.02) |
| SGI: 1.94 (Revenue 39.0m / 20.1m) |
| TATA: 0.03 (NI -16.2m - CFO -20.0m) / TA 148.0m) |
| Beneish M = 10.11 (Cap -4..+1) = D |
As of June 19, 2026, the stock is trading at USD 7.66 with a total of 8,700,646 shares traded.
Over the past week, the price has changed by +11.66%,
over one month by -4.73%,
over three months by -25.63% and
over the past year by +175.54%.
United States Antimony has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy UAMY.
- StrongBuy: 3
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 13.1 | 70.5% |
P/E Forward = 74.6269
P/S = 29.074
P/B = 7.9663
Revenue TTM = 39.0m USD
EBIT TTM = -19.8m USD
EBITDA TTM = -18.4m USD
Long Term Debt = 23.5k USD (from longTermDebt, last quarter)
Short Term Debt = 166k USD (from shortTermDebt, last quarter)
Debt = 215k USD (from shortLongTermDebtTotal, last quarter) + Leases 38.2k
Net Debt = -3.01m USD (calculated: Debt 215k - CCE 3.22m)
Enterprise Value = 1.13b USD (1.14b + Debt 215k - CCE 3.22m)
Interest Coverage Ratio = unknown (Ebit TTM -19.8m / Interest Expense TTM 0.0)
EV/FCF = -19.01x (Enterprise Value 1.13b / FCF TTM -59.5m)
FCF Yield = -5.26% (FCF TTM -59.5m / Enterprise Value 1.13b)
FCF Margin = -152.5% (FCF TTM -59.5m / Revenue TTM 39.0m)
Net Margin = -41.44% (Net Income TTM -16.2m / Revenue TTM 39.0m)
Gross Margin = 7.00% ((Revenue TTM 39.0m - Cost of Revenue TTM 36.3m) / Revenue TTM)
Gross Margin QoQ = -70.32% (prev 20.34%)
Tobins Q-Ratio = 7.65 (Enterprise Value 1.13b / Total Assets 148.0m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 215k)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -15.6m (EBIT -19.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.62 (Total Current Assets 48.4m / Total Current Liabilities 13.4m)
Debt / Equity = 0.00 (Debt 215k / totalStockholderEquity, last quarter 131.9m)
Debt / EBITDA = 0.16 (negative EBITDA) (Net Debt -3.01m / EBITDA -18.4m)
Debt / FCF = 0.05 (negative FCF - burning cash) (Net Debt -3.01m / FCF TTM -59.5m)
Total Stockholder Equity = 95.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -17.25% (Net Income -16.2m / Total Assets 148.0m)
RoE = -16.94% (Net Income TTM -16.2m / Total Stockholder Equity 95.5m)
RoCE = -20.67% (EBIT -19.8m / Capital Employed (Equity 95.5m + L.T.Debt 23.5k))
RoIC = -11.74% (negative operating profit) (NOPAT -15.6m / Invested Capital 132.9m)
WACC = 10.98% (E(1.14b)/V(1.14b) * Re(10.98%) + D(215k)/V(1.14b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.98% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 82.22 | Cagr: 12.96%
[DCF] Fair Price = unknown (Cash Flow -59.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -3.98 | # QB: -1
Revenue Correlation: 97.54 | Revenue CAGR: 107.8% | SUE: -3.24 | # QB: -1
EPS current Quarter (2026-06-30): EPS=-0.01 | Chg30d=+70.00% | Revisions=+20% | Analysts=2
EPS next Quarter (2026-09-30): EPS=0.03 | Chg30d=+142.86% | Revisions=+20% | Analysts=2
EPS current Year (2026-12-31): EPS=0.10 | Chg30d=+145.24% | Revisions=+20% | GrowthEPS=+337.5% | GrowthRev=+205.1%
EPS next Year (2027-12-31): EPS=0.34 | Chg30d=+161.54% | Revisions=+20% | GrowthEPS=+257.9% | GrowthRev=+111.9%
[Analyst] Revisions Ratio: +20%